Immunotherapy of respiratory syncytial virus pneumonia following bone marrow transplantation

John Devincenzo, D. Leombruno, R. J. Soiffer, G. R. Siber

Research output: Contribution to journalArticle

42 Citations (Scopus)

Abstract

Respiratory syncytial virus (RSV) pneumonia is a well-recognized complication of bone marrow transplantation with a high mortality rate. We describe two patients who developed RSV pneumonia within the first 3 weeks following allogeneic bone marrow transplantation. These patients had significant oxygen requirements and radiographic infiltrates. Both were treated with aerosolized ribavirin and given a single 1.5 gm/kg dose of intravenous immune globulin containing high levels of RSV neutralizing activity (RSV-IG). Both patients showed subjective and objective improvement after RSV-IG, never required mechanical ventilation, and were discharged without an oxygen requirement within 2 weeks after therapy. RSV microneutralization activity was measured in serum and nasal secretions. Mean serum microneutralization activity increased from 2279 microneutralization units (Mu)/ml to 18,082 Mu/ml after RSV-IG. Peak serum microneutralization activity achieved with RSV-IG was higher than that achieved in a series of other immunocompromised adults with RSV pneumonia given either multiple doses of standard IVIG or no immune globulin therapy. RSV-IG may be beneficial in the treatment of RSV pneumonia in severely immunocompromised patients.

Original languageEnglish (US)
Pages (from-to)1051-1056
Number of pages6
JournalBone Marrow Transplantation
Volume17
Issue number6
StatePublished - Jun 1 1996

Fingerprint

Respiratory Syncytial Viruses
Bone Marrow Transplantation
Immunotherapy
Pneumonia
Intravenous Immunoglobulins
Serum
Oxygen
Ribavirin
Homologous Transplantation
Immunocompromised Host
Nose
Artificial Respiration
Immunoglobulins
Therapeutics

All Science Journal Classification (ASJC) codes

  • Hematology
  • Transplantation

Cite this

Immunotherapy of respiratory syncytial virus pneumonia following bone marrow transplantation. / Devincenzo, John; Leombruno, D.; Soiffer, R. J.; Siber, G. R.

In: Bone Marrow Transplantation, Vol. 17, No. 6, 01.06.1996, p. 1051-1056.

Research output: Contribution to journalArticle

Devincenzo, John ; Leombruno, D. ; Soiffer, R. J. ; Siber, G. R. / Immunotherapy of respiratory syncytial virus pneumonia following bone marrow transplantation. In: Bone Marrow Transplantation. 1996 ; Vol. 17, No. 6. pp. 1051-1056.
@article{833488e3429b492787800fe145606220,
title = "Immunotherapy of respiratory syncytial virus pneumonia following bone marrow transplantation",
abstract = "Respiratory syncytial virus (RSV) pneumonia is a well-recognized complication of bone marrow transplantation with a high mortality rate. We describe two patients who developed RSV pneumonia within the first 3 weeks following allogeneic bone marrow transplantation. These patients had significant oxygen requirements and radiographic infiltrates. Both were treated with aerosolized ribavirin and given a single 1.5 gm/kg dose of intravenous immune globulin containing high levels of RSV neutralizing activity (RSV-IG). Both patients showed subjective and objective improvement after RSV-IG, never required mechanical ventilation, and were discharged without an oxygen requirement within 2 weeks after therapy. RSV microneutralization activity was measured in serum and nasal secretions. Mean serum microneutralization activity increased from 2279 microneutralization units (Mu)/ml to 18,082 Mu/ml after RSV-IG. Peak serum microneutralization activity achieved with RSV-IG was higher than that achieved in a series of other immunocompromised adults with RSV pneumonia given either multiple doses of standard IVIG or no immune globulin therapy. RSV-IG may be beneficial in the treatment of RSV pneumonia in severely immunocompromised patients.",
author = "John Devincenzo and D. Leombruno and Soiffer, {R. J.} and Siber, {G. R.}",
year = "1996",
month = "6",
day = "1",
language = "English (US)",
volume = "17",
pages = "1051--1056",
journal = "Bone Marrow Transplantation",
issn = "0268-3369",
publisher = "Nature Publishing Group",
number = "6",

}

TY - JOUR

T1 - Immunotherapy of respiratory syncytial virus pneumonia following bone marrow transplantation

AU - Devincenzo, John

AU - Leombruno, D.

AU - Soiffer, R. J.

AU - Siber, G. R.

PY - 1996/6/1

Y1 - 1996/6/1

N2 - Respiratory syncytial virus (RSV) pneumonia is a well-recognized complication of bone marrow transplantation with a high mortality rate. We describe two patients who developed RSV pneumonia within the first 3 weeks following allogeneic bone marrow transplantation. These patients had significant oxygen requirements and radiographic infiltrates. Both were treated with aerosolized ribavirin and given a single 1.5 gm/kg dose of intravenous immune globulin containing high levels of RSV neutralizing activity (RSV-IG). Both patients showed subjective and objective improvement after RSV-IG, never required mechanical ventilation, and were discharged without an oxygen requirement within 2 weeks after therapy. RSV microneutralization activity was measured in serum and nasal secretions. Mean serum microneutralization activity increased from 2279 microneutralization units (Mu)/ml to 18,082 Mu/ml after RSV-IG. Peak serum microneutralization activity achieved with RSV-IG was higher than that achieved in a series of other immunocompromised adults with RSV pneumonia given either multiple doses of standard IVIG or no immune globulin therapy. RSV-IG may be beneficial in the treatment of RSV pneumonia in severely immunocompromised patients.

AB - Respiratory syncytial virus (RSV) pneumonia is a well-recognized complication of bone marrow transplantation with a high mortality rate. We describe two patients who developed RSV pneumonia within the first 3 weeks following allogeneic bone marrow transplantation. These patients had significant oxygen requirements and radiographic infiltrates. Both were treated with aerosolized ribavirin and given a single 1.5 gm/kg dose of intravenous immune globulin containing high levels of RSV neutralizing activity (RSV-IG). Both patients showed subjective and objective improvement after RSV-IG, never required mechanical ventilation, and were discharged without an oxygen requirement within 2 weeks after therapy. RSV microneutralization activity was measured in serum and nasal secretions. Mean serum microneutralization activity increased from 2279 microneutralization units (Mu)/ml to 18,082 Mu/ml after RSV-IG. Peak serum microneutralization activity achieved with RSV-IG was higher than that achieved in a series of other immunocompromised adults with RSV pneumonia given either multiple doses of standard IVIG or no immune globulin therapy. RSV-IG may be beneficial in the treatment of RSV pneumonia in severely immunocompromised patients.

UR - http://www.scopus.com/inward/record.url?scp=0030057423&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0030057423&partnerID=8YFLogxK

M3 - Article

VL - 17

SP - 1051

EP - 1056

JO - Bone Marrow Transplantation

JF - Bone Marrow Transplantation

SN - 0268-3369

IS - 6

ER -